GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

CureVac B.V

The deal represents a vote of confidence in the future of the mRNA-based vaccine market.

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker's vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech.

GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac

U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vaccines.

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

PayPal

Visa

For investors with a long-term mindset, there's never a wrong time to put your money to work on Wall Street. Most online brokers have eliminated minimum deposit requirements and commission fees for common stock trades.

3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024

GSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new mRNA vaccines for influenza and COVID-19 under a €1.45 billion deal. Under a new agreement with Germany's CureVac, the UK drugs giant will be ceded the rights to develop, manufacture, and sell these vaccines generated by the partnership.

GSK takes full control of flu vaccine programme in €1.45bn deal

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.

GSK buys full rights to make COVID, influenza vaccines from CureVac

Moderna

Pfizer

The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.

CDC Narrows Age Recommendation for Use of RSV Vaccine

Bristol-Myers

The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.

You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.

British biotech stock GSK plc (NYSE:GSK) is trading lower, though it pared its steeper losses today, down 1% at $38.49 at last glance after earlier sliding as much as 7%.

Biotech Stock Slips on CDC Buzz

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine. Pfizer and Moderna, which also make RSV vaccines, fell 2% and 11% in New York overnight.

GSK and Moderna slide on RSV vaccine CDC updates

GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.

GSK stock falls more at London open following RSV vaccination news

GSK PLC (LSE:GSK, NYSE:GSK) is attempting to drive the FTSE 100 lower after it plunged close to 7% following a ruling in the US that restricted the use of its RSV vaccine. The US Advisor Committee on Immunisation Practises announced all those over the age of 75 should only have a single dose of the treatment.

GSK plummets as US restricts RSV vaccine

GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending their use for those under 60 years of age.

GSK slides 6% after US CDC narrows scope of RSV shots

Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.

Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations

A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

US advisers to consider RSV shots as GSK looks to keep market lead

The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.

GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance

GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent committed” to keeping its listing in the UK. Speaking at the Time CEO Summit, boss Emma Walmsley said that even though only 3 per cent of its business is in Britain, GSK switching its listing was "not a debate for us.

GSK 100% backs London listing, says boss

Innoviva

Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership will provide GSK with access to Ochre Bio's computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. The collaboration will enable Ochre Bio and GSK to deepen the unders.

GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease

GSK PLC (LSE:GSK, NYSE:GSK) is 'still appealing' - even in the wake of a significant legal setback, according to regional broker Shore Capital, which set out its 'buy' case in the wake of the UK drug giant's decision to challenge a key US court ruling. The Delaware state court ruling allowed plaintiffs' expert testimony in Zantac trials, contrary to a previous Federal court decision dismissing all multi-district litigation (MDL) cases.

GSK 'still appealing' despite US legal setback says broker

GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting over 70,000 lawsuits claiming Zantac causes cancer.  Analysts had expected the UK drug giant, along with Pfizer, Sanofi and Boehringer Ingelheim to contest the original ruling.

GSK appeals Delaware Zantac ruling

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

GSK PLC (LSE:GSK, NYSE:GSK) has confirmed that the US Food & Drug Administration has approved Arexvy for preventing respiratory syncytial virus (RSV) in adults aged 50 to 59 at increased risk of severe outcomes from the cold-like infection. GSK estimates over 13 million US adults fall into this category.

GSK RSV jab receives label expansion from US regulator

PHILADELPHIA--(BUSINESS WIRE)-- #Adult--US FDA approves expanded age indication for GSK's AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.

News for GlaxoSmithKline Stock (GSK)